Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lessened its position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 70.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,560 shares of the medical research company's stock after selling 8,426 shares during the quarter. Intech Investment Management LLC's holdings in Exact Sciences were worth $200,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in EXAS. Thompson Investment Management Inc. grew its position in shares of Exact Sciences by 17.8% during the fourth quarter. Thompson Investment Management Inc. now owns 241,774 shares of the medical research company's stock worth $13,585,000 after acquiring an additional 36,505 shares during the last quarter. Zacks Investment Management acquired a new stake in Exact Sciences during the 3rd quarter worth $2,083,000. Charles Schwab Investment Management Inc. grew its position in Exact Sciences by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company's stock worth $88,017,000 after purchasing an additional 45,015 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Exact Sciences by 35.3% in the fourth quarter. Harbor Capital Advisors Inc. now owns 95,827 shares of the medical research company's stock valued at $5,385,000 after purchasing an additional 24,992 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in shares of Exact Sciences by 32.2% in the fourth quarter. Jones Financial Companies Lllp now owns 9,508 shares of the medical research company's stock valued at $534,000 after buying an additional 2,315 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EXAS. Scotiabank raised their price target on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a report on Monday, February 24th. Benchmark reiterated a "buy" rating and issued a $65.00 target price on shares of Exact Sciences in a research note on Monday, January 13th. Royal Bank of Canada assumed coverage on Exact Sciences in a research note on Thursday, March 13th. They set a "sector perform" rating and a $52.00 price target for the company. Guggenheim set a $60.00 price objective on shares of Exact Sciences and gave the company a "buy" rating in a research report on Friday. Finally, Piper Sandler cut their price objective on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $70.26.

Exact Sciences Trading Down 3.0 %

Shares of Exact Sciences stock traded down $1.33 during trading hours on Friday, reaching $43.66. 1,336,419 shares of the company's stock were exchanged, compared to its average volume of 2,626,482. The firm has a market capitalization of $8.11 billion, a price-to-earnings ratio of -7.84 and a beta of 1.25. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The company has a fifty day moving average of $49.71 and a 200-day moving average of $57.75.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. Sell-side analysts forecast that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.